Transcription factors: molecular targets for prostate cancer intervention by phytochemicals.

abstract：:In this early phase of the new era of molecularly targeted patient friendly cancer chemotherapy, there is a need for novel viable anticancer molecular targets. The MDM2 oncoprotein has been validated as a potential target for cancer drug development. MDM2 amplification and/or overexpression occur in a wide variety of ...

journal_title：Current cancer drug targets

authors： Buolamwini JK,Addo J,Kamath S,Patil S,Mason D,Ores M

更新日期：2005-02-01 00:00:00

abstract：:Oncolytic viruses can selectively replicate in and lead to tumor cell lysis with minimal infection/replication potential in adjoining non-neoplastic tissue. Because of paramount safety concerns, first-generation oncolytic viruses were designed to be significantly attenuated in their lytic potential. Results from recen...

journal_title：Current cancer drug targets

authors： Hardcastle J,Kurozumi K,Chiocca EA,Kaur B

更新日期：2007-03-01 00:00:00

abstract：:Cancer is a disease in which cellular growth regulatory networks are disrupted. Lesions in well-characterized oncogenes and tumor suppressors often contribute to the dysregulation, but recent work has also uncovered the fundamental importance of enzymes that modulate the acetylation status of chromatin to the initiati...

journal_title：Current cancer drug targets

authors： Chen JS,Faller DV,Spanjaard RA

更新日期：2003-06-01 00:00:00

abstract：:Cetuximab (IMC-C225, Erbitux ImClone Systems Inc, New York, NY) is a recombinant, human/mouse chimeric monoclonal antibody (MAb) that binds specifically to the extracellular domain of the human epidermal growth factor receptor (EGFR) on both normal and tumor cells, and competitively inhibits the binding of epidermal g...

journal_title：Current cancer drug targets

authors： Vincenzi B,Zoccoli A,Pantano F,Venditti O,Galluzzo S

更新日期：2010-02-01 00:00:00

abstract：:An apparent low prevalence of cancer in hypertensive patients receiving angiotensin converting enzyme inhibitors is reported; however, the molecular mechanisms have not been elucidated. Angiotensin-II (Ang-II) is well known to be associated with hypertension, as a main peptide of the renin-angiotensin system, and its ...

journal_title：Current cancer drug targets

authors： Uemura H,Nakaigawa N,Ishiguro H,Kubota Y

更新日期：2005-08-01 00:00:00

abstract：:Cyclooxygenase-2 (COX-2) is a critical enzyme implicated in chronic inflammation-associated cancer development. Our studies have shown that the exposure of Beas-2B cells, a human bronchial epithelial cell line, to lung carcinogenic nickel compounds results in increased COX-2 expression. However, the signaling pathways...

journal_title：Current cancer drug targets

authors： Cai T,Li X,Ding J,Luo W,Li J,Huang C

更新日期：2011-06-01 00:00:00

abstract：:CXCR4 is a chemokine receptor implicated in the metastatic process. The CXCR4 ligand, CXCL12, was shown to bind also the CXCR7 receptor, a recently deorphanized chemokine receptor whose signalling pathway and function are still controversial. This study was conducted to determine patients clinic-pathological factors a...

journal_title：Current cancer drug targets

authors： D'Alterio C,Consales C,Polimeno M,Franco R,Cindolo L,Portella L,Cioffi M,Calemma R,Marra L,Claudio L,Perdonà S,Pignata S,Facchini G,Cartenì G,Longo N,Pucci L,Ottaiano A,Costantini S,Castello G,Scala S

更新日期：2010-11-01 00:00:00

abstract：:Amplification of the HER-2 gene occurs in approximately 25% of breast cancers, causing up-regulation of key signaling pathways which control cell growth and survival. In breast cancer patients, HER-2 overexpression correlates with an aggressive phenotype and poor prognosis. HER-2, therefore, has become the focus of ma...

journal_title：Current cancer drug targets

authors： Browne BC,O'Brien N,Duffy MJ,Crown J,O'Donovan N

更新日期：2009-05-01 00:00:00

abstract：:Drug delivery systems are under intense investigation all around the world, especially in oncology research. Indeed, in some cases, like bone metastasis, nanodrugs may represent the last and best choice for both treatment and imaging of early cancer foci. Nuclear medicine has been using MDP labelled with 99mTc as radi...

journal_title：Current cancer drug targets

authors： Coelho BF,de Souza Albernaz M,Iscaife A,Moreira Leite KR,de Souza Junqueira M,Bernardes ES,da Silva EO,Santos-Oliveira R

更新日期：2015-01-01 00:00:00

abstract：:Lipophilic derivatives of the anticancer drug paclitaxel (PTX) were prepared by means of its conjugation to lipoamino acid (LAA) residues, with the aim of increasing drug accumulation in tumor cells. PTX was linked to the methyl esters of norleucine (C6) or 2-aminodecanoic acid (C10). A succinic acid group was used as...

journal_title：Current cancer drug targets

authors： Pignatello R,Paolino D,Pantò V,Pistară V,Calvagno MG,Russo D,Puglisi G,Fresta M

更新日期：2009-03-01 00:00:00

abstract：BACKGROUND:Osteosarcoma is an aggressive bone tumor. Itrepresents the principal cause of cancer-associated death in children.Considering the recent findings on the role of iron in cancer, iron chelation has been investigated for its antineoplastic properties in many tumors. Deferasirox is the most used iron chelator co...

journal_title：Current cancer drug targets

authors： Argenziano M,Di Paola A,Tortora C,Di Pinto D,Pota E,Di Martino M,Perrotta S,Rossi F,Punzo F

更新日期：2020-12-29 00:00:00

abstract：:The greatest risk factor for the development of cervical and other cancers that have been linked to the human papillomavirus (HPV) family is the persistence of the virus. To persist for the decades required to develop HPV-related cancers, the virus must escape host immunity. HPV is a simple DNA virus that has evolved ...

journal_title：Current cancer drug targets

authors： Kanodia S,Fahey LM,Kast WM

更新日期：2007-02-01 00:00:00

abstract：:The Jun oncoprotein is a major component of the transcription factor complex AP-1, which regulates the expression of multiple genes essential for cell proliferation, differentiation and apoptosis. Constitutive activation of endogenous AP-1 is required for tumor formation in avian and mammalian cell transformation syst...

journal_title：Current cancer drug targets

authors： Hartl M,Bader AG,Bister K

更新日期：2003-02-01 00:00:00

abstract：:Androgen deprivation therapy has been the major treatment for advanced prostate cancer (PCa) and has shown to prolong life. However, remissions are temporary and patients almost inevitably progress to become castration-resistant prostate cancer (CRPC). CRPC is almost incurable even when treated with docetaxel that may...

journal_title：Current cancer drug targets

authors： Donkena KV,Yuan H,Young CY

更新日期：2010-06-01 00:00:00

abstract：:Hepatocellular carcinoma (HCC), considered to be one of the most lethal cancers with almost > 1 million deaths reported annually worldwide, remains a devastating disease with no known effective cure. Hence, chemopreventive strategies come into play, offering an effective and safe mode of treatment, ideal to ward off p...

journal_title：Current cancer drug targets

authors： Thoppil RJ,Bhatia D,Barnes KF,Haznagy-Radnai E,Hohmann J,Darvesh AS,Bishayee A

更新日期：2012-11-01 00:00:00

abstract：:Although the imatinib based therapy of chronic myeloid leukemia (CML) represents a triumph of medicine, not all patients with CML benefit from this drug due to the development of resistance and intolerance. The interruption of imatinib treatment is often followed by clinical relapse, suggesting a failure in the killin...

journal_title：Current cancer drug targets

authors： Adamia S,Pilarski PM,Bar-Natan M,Stone RM,Griffin JD

更新日期：2013-09-01 00:00:00

abstract：:Prevention is one of the most important and promising strategies to control cancer. Many dietary bioactive compounds, mostly phytochemicals, have been found to decrease the risk of carcinogenesis. Modulating the metabolism and disposition pathways of carcinogens represents one of the major mechanisms by which dietary ...

journal_title：Current cancer drug targets

authors： Yu S,Kong AN

更新日期：2007-08-01 00:00:00

abstract：:Head and neck cancer, the sixth most common type of cancer worldwide, is associated with a dismal prognosis that has minimally improved during the last few decades. Future advances in the treatment and prognosis of this fatal disease largely rely upon a better understanding of the molecular events that underlie tumor ...

journal_title：Current cancer drug targets

authors： Nikitakis NG,Siavash H,Sauk JJ

更新日期：2004-12-01 00:00:00

abstract：:There is an emerging paradigm shift in oncology that seeks to emphasize molecularly targeted approaches for cancer prevention and therapy. Chalcones (1,3-diphenyl-2-propen-1-ones), naturally-occurring compounds with widespread distribution in spices, tea, beer, fruits and vegetables, consist of open-chain flavonoids i...

journal_title：Current cancer drug targets

authors： Jandial DD,Blair CA,Zhang S,Krill LS,Zhang YB,Zi X

更新日期：2014-01-01 00:00:00

abstract：:The experimental cytotoxic drug cyclopentenyl cytosine (CPEC) is an analogue of cytidine. Besides its antiviral effect, its potential use in the treatment of cancer has become an important area of research. CPEC is activated by intracellular phosphorylation ultimately forming its metabolite CPEC-TP. CPEC-TP is a non c...

journal_title：Current cancer drug targets

authors： Schimmel KJ,Gelderblom H,Guchelaar HJ

更新日期：2007-08-01 00:00:00

abstract：:Chronic myeloid leukemia (CML) is a myeloproliferative disorder caused by the Philadelphia-positive chromosome deriving from a translocation between chromosomes 22 and 9. The oncogenic product of this aberrant chromosome is the constitutively active tyrosine kinase BCR-ABL that is responsible for leukemic cell growth,...

journal_title：Current cancer drug targets

authors： Stefanachi A,Leonetti F,Nicolotti O,Catto M,Pisani L,Cellamare S,Altomare C,Carotti A

更新日期：2012-06-01 00:00:00

abstract：:Therapeutic vaccines continue to be one of the most active fields in cancer research. However, despite clear evidence of antitumor effect in laboratory animals, and despite the ability of current vaccine candidates to elicit tumor specific antibodies and T-cells in humans, objective responses in the clinical trials ar...

journal_title：Current cancer drug targets

authors： Gonzalez G,Crombet T,Lage A

更新日期：2011-01-01 00:00:00

abstract：:The capacity to induce new blood vessel formation or to repair damaged vessels is an attractive idea that has, for a long time, captured the attention and imagination of researchers. Beside the identification of the pro-angiogenic growth factors and their counterpart inhibitors, the discovery of endothelial progenitor...

journal_title：Current cancer drug targets

authors： Pasquier E,Dias S

更新日期：2010-12-01 00:00:00

abstract：:FOXO proteins are evolutionarily conserved transcription factors implicated in several fundamental cellular processes, functioning as end-point for transcriptional programs involved in apoptosis, stress response and longevity. Abrogation of FOXO function is very frequent in human cancer, therefore the mechanisms of re...

journal_title：Current cancer drug targets

authors： Zanella F,Link W,Carnero A

更新日期：2010-03-01 00:00:00

abstract：:Inactivation of the FHIT and TP53 genes is frequently observed in primary non-small cell lung cancers (NSCLC) and cell lines and may contribute to resistance to apoptotic stimuli elicited by various anti-tumor drugs. To evaluate a possible relationship between FHIT and TP53 status and response to platinum-analogue reg...

journal_title：Current cancer drug targets

authors： Cortinovis DL,Andriani F,Livio A,Fabbri A,Perrone F,Marcomini B,Pilotti S,Mariani L,Bidoli P,Bajetta E,Roz L,Sozzi G

更新日期：2008-08-01 00:00:00

abstract：BACKGROUND:CYP1B1 is recognized as a valuable target for chemotherapy. It catalyzes the bioactivation of naphthoquinone oximes within certain cancer cell lines. However, the expression level of CYP1B1 in melanoma and the functional role regulating the activity of DMAKO-20 as a representative naphthoquinone oxime agains...

journal_title：Current cancer drug targets

authors： Cui J,Zhou X,Huang J,Cui J,Chen J

更新日期：2020-11-15 00:00:00

abstract：:Sporadic colorectal cancer develops through a number of functional mutations. Key events are mutually exclusive mutations in BRAF or RAS oncogenes. Signatures for BRAF oncogene have been revealed in melanoma. In a previous study we have reported a molecular signature for HRAS and KRAS mutations in colorectal cell line...

journal_title：Current cancer drug targets

authors： Joyce T,Oikonomou E,Kosmidou V,Makrodouli E,Bantounas I,Avlonitis S,Zografos G,Pintzas A

更新日期：2012-09-01 00:00:00

abstract：:Gastrointestinal (GI) tumors are among the leading cause of death in cancer patients worldwide. Particularly, gastric cancer (GC) is the third cause of cancer deaths, whereas esophageal neoplasm is the eighth leading most common cancer worldwide and its incidence, especially adenocarcinoma type, is continuously increa...

journal_title：Current cancer drug targets

authors： Berretta M,Romano C,Di Francia R,De Diviitis C,Canzonieri V,Caraglia M,Facchini G,Nasti G

更新日期：2018-01-01 00:00:00

abstract：:The resistance of tumors to a number of structurally and functionally unrelated chemotherapeutic drugs has been a major obstacle for successful cancer chemotherapy. An important mechanism leading to multidrug resistance (MDR) is the overexpression of the 170 kDa P-glycoprotein (P-gp), which is a member of the ATP-bind...

journal_title：Current cancer drug targets

authors： Santos SA,Paulo A

更新日期：2013-10-01 00:00:00

abstract：:The genomic characterization of acute myeloid leukemia (AML) by DNA sequencing has illuminated subclasses of the disease, with distinct driver mutations, that might be responsive to targeted therapies. Approximately 15-23% of AML genomes harbor mutations in one of two isoforms of isocitrate dehydrogenase (IDH1 or IDH2...

journal_title：Current cancer drug targets

authors： Becker JS,Fathi AT

更新日期：2020-01-01 00:00:00